Interim Chief Executive Officer, Chief Technical Officer and Director
Robert Beecroft is the founder and Chief Technical Officer of ImmunoPrecise and previously served as its Chief Executive Officer and President. Mr. Beecroft has over 25 years’ experience in the development of innovative and proprietary methods for the production of monoclonal and polyclonal antibodies and peptides. Mr. Beecroft has a B.Sc. in Microbiology from University of Victoria and has been involved in over 15 Research Projects over the course of the last 25 years and been an instructor for graduate students at the University of Victoria on the use and production of monoclonal antibodies for over 13 years. In 2015, Mr. Beecroft was the recipient of the UVic Distinguished Alumni Award for the Faculty of Science, in recognition for being the Founder of ImmunoPrecise Antibodies Ltd.
James Kuo, MD, MBA
Interim President and Chairman
Dr. James Kuo brings considerable global life science business experience to ImmunoPrecise. Currently, he serves as Chief Executive Officer of the Finnish biotechnology company, FIT Biotech. He has also been Chairman and Chief Executive Officer of Synthetic Biologics and BioMicro Systems and Chief Executive Officer of Discovery Laboratories. In addition to these senior biotech leadership roles, Dr. Kuo has been head of business development at Myriad Genetics and Associate Director of Corporate Licensing and Development at Pfizer. He has further served as Managing Director of HealthCare Ventures, a $378 million venture capital fund, and is presently Managing Director at Athena Bioventures in La Jolla, CA. He is also a founder and Chairman of Monarch Labs. Dr. Kuo received his MD from the University of Pennsylvania School of Medicine and his MBA from the Wharton School of Business. He received his BA in molecular biology from Haverford College.
Chief Scientific Officer
Dr. Dryhurst has been with ImmunoPrecise since 2010. She received an NSERC Industrial Research and Development Postdoctoral Fellowship to work on a platform for rabbit monoclonal antibody development at ImmunoPrecise Antibodies. Rabbit monoclonal antibodies are now a key part of what ImmunoPrecise provides to its clients. She is currently in charge of R&D at ImmunoPrecise where she is responsible for prioritization of research projects, alignment with corporate strategy and developing new product introductions. She received her B.Sc. in Biology, and her Ph.D. in Biochemistry and Molecular Biology from the University of Victoria.
VP, Marketing and Sales Support
Teri Otto joined ImmunoPrecise in 1997 as a co-op student and continued as a fulltime employee upon graduation in 2000. She began as a technician and animal care manager. She has been a key part of developing ImmunoPrecise’s successful laboratory operations and antibody engineering capabilities, particularly in the area of mouse hybridomas. Ms. Otto holds a B.Sc. (with distinction) from University of Victoria in Microbiology and Associate Degrees in Psychology, Bio Chemistry, and Applied Chemistry from Camosum College in Victoria, BC.
Vice President of Corporate Services
Dr. Kevin Wong has served as President of ImmunoPrecise and Vice President of Corporate Services since joining the company in 2013. Dr. Wong has previous experience working in both industry and academic settings. He managed the laboratory operations for Protox Therapeutics for nine years prior to joining ImmunoPrecise. Dr. Wong spent six years at Cambridge University as a Research Associate in both the Departments of Biochemistry and Pathology, as well as two years as a Research Associate at University of Ottawa Department of Cellular and Molecular Medicine. Dr. Wong graduated from the University of Victoria with a Ph.D. in Biochemistry. Dr. Wong has been published in more than a dozen peer-reviewed articles in journals of biological sciences.